Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Armour is boosting its plasma fraction business by adding 10 Behringwerke AG plasma derivative products for eventual marketing in the U.S., according to a March 27-announced agreement between Armour parent Revlon and the Hoechst GmbH subsidiary. The agreement, Revlon said, "also provides Armour with U.S. marketing rights to certain future new products developed by Behringwerke." Among the Behringwerke products Armour hopes to market in the U.S. in the near future are Venimmun I.V. gammaglobulin, indicated to restore the natural immune response in certain patient populations such as gammaglobulin deficient disease and burn victims; Cytomegaloimmunoglobulin, an I.V. globulin preparation containing high titers of cytomegalovirus antibodies indicated for use in patient populations exposed to or at risk of infection; and PBsB Concentrate (a Factor 9 complex product) stabilized and heated in liquid form to prevent viral contamination, and indicated for the treatment of hemophilia where patients were deficient in Factor 9. Another of the products under the agreement is hematin, derived from outdated red blood cells, for the treatment of intermittent porphyria. Last July, Abbott's hematin product Panhematin was approved by FDA on the basis of studies in the literature not performed by the company. None of the 10 Behringwerke plasma derivatives are currently approved for marketing in the U.S. Revlon stated that while "Behringwerke is one of the leading mfrs. of plasma fractions in the world," it "does not presently distribute such fractions in this country." Armour is "presently among the leading companies in the U.S. in plasma fractions sales and the largest domestic distributor of blood coagulation products which are used by hemophiliacs to control bleeding," Revlon said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts